Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP595 | DOI: 10.1530/endoabs.90.EP595

1Hospital Dr. Nélio Mendonça, Funchal, Portugal; 2São João Universitary Hospital Center, Porto, Portugal

Background: Immune checkpoint inhibitors (ICI) are an innovative oncologic therapy used in several types of solid and hematological neoplasms. This treatment enables the antitumoral immune system response and results in significant improvement of clinical outcomes and survival rate. However, endocrine related adverse effects (ERAE) have been related, with thyroid and pituitary dysfunction being the most common endocrine diseases described. An association between the surge of endocrinopathies and better overall survival rate has been suggested.

Aim: To evaluate the association between patients’ features and the development of endocrine toxicity and to assess the association between ERAE development and mortality.

Methods: A retrospective observational study was conducted in 98 patients submitted to immunotherapy in our center since its introduction in 2015 until March 2021. We excluded patients who had missing data regarding the corticotroph axis evaluation. We used linear and logistic regression models to address our aims.

Results: We observed a significant negative association between ERAE development and death (OR 0.32; P=0.028). We detected no associations between ERAE and the following characteristics: age at ICI initiation, sex, diabetes mellitus, medical history, immunotherapy duration and ICI type.

Conclusion: The development of an ERAE may be associated with a better overall survival rate in advanced oncologic disease supporting the role of an unleashed immune system response to malignant cells.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.